LEGACY Study Data
The LEGACY study is a robust multicenter study confirming TheraSphere as a neoadjuvant or standalone therapy in treating HCC. 100% of patients in the Legacy study responded to TheraSphere treatment(s), with a 93% Overall Survival rate at 3 years for those who underwent transplant or resection. 45 patients in the study were successfully bridged to a liver transplant or surgical resection following TheraSphere. LEGACY is the first multicenter study to report a high median perfused volume absorbed dose of 410 Gy with TheraSphere, which resulted in an 88% best response, excellent and durable tumor control and high overall survival rate in patients with early and advanced HCC.